Symptomatic Bradycardia Due to Alectinib in a Patient with Advanced Stage of NSCLC

Symptomatic Bradycardia Due to Alectinib in a Patient with Advanced Stage of NSCLC

Alectinib is one of the targeted therapies commonly given to patients with advanced non-small cell lung cancer (NSCLC) with mutations in the ALK gene. The most common adverse effects of alectinib are fatigue, constipation, edema, myalgia and anemia. Meanwhile, bradycardia was reported as a very comm...

Full description

Saved in:
Bibliographic Details
Main Authors: Ceva Wicaksono Pitoyo, Cleopas Martin Rumende, Anindita Kartika Wiraputri, Fatira Ratri Audita
Format: Article
Language:English
Published: Interna Publishing 2022-07-01
Series:Acta Medica Indonesiana
Subjects:
alectinib
bradycardia
NSCLC
Online Access:http://www.actamedindones.org/index.php/ijim/article/view/2095
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items